News - Anti-Arthritics/Rheumatics

Filter

Popular Filters

82 to 106 of 297 results

Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors

17-06-2013

Bazedoxifene, a drug approved in some countries to treat osteoporosis, has now been shown to stop the…

Anti-Arthritics/RheumaticsbazedoxifeneOncologyPfizerPharmaceuticalResearch

Bristol-Myers and Simcere agree to co-develop/commercialize Orencia SC in China

14-06-2013

US pharma major Bristol-Myers Squibb (NYSE: BMY) and China-based Simcere Pharmaceutical (NYSE: SCR) have…

Anti-Arthritics/RheumaticsAsia-PacificBiotechnologyBristol-Myers SquibbLicensingOrenciaPharmaceuticalSimcere Pharmaceutical

EULAR highlights: Celgene's apremilast; AbbVie's Humira; and Lilly's baricitinib

13-06-2013

Among highlights of the ongoing European League Against Rheumatism (EULAR) in Madrid, Spain, US biotech…

AbbVieAnti-Arthritics/RheumaticsapremilastbaricitinibBiotechnologyCelgeneEli LillyHumiramethotrexatePharmaceuticalResearch

Generics triple-therapy just as effective as brand-name Enbrel, new study shows

13-06-2013

Global biotech leader Amgen's (Nasdaq: AMGN) branded drug Enbrel (etanercept) is no more effective in…

AmgenAnti-Arthritics/RheumaticsEnbrelGenericsmethotrexatePharmaceuticalResearch

Bristol-Myers Orencia equals Humira in head-to-head AMPLE RA study

12-06-2013

US drug major Bristol-Myers Squibb (NYSE: BMY) has announced the results of year two data from AMPLE…

AbbVieAnti-Arthritics/RheumaticsBristol-Myers SquibbHumiraOrenciaPharmaceuticalResearch

Regulatory briefs: Sanofi's Fluzone; Roche' RoActemra; Takeda's Rienso

10-06-2013

French pharma major Sanofi (Euronext: SAN) today (June 10) announced that the US Food and Drug Administration…

Anti-Arthritics/RheumaticsBiotechnologyPharmaceuticalRegulationRocheSanofiTakeda PharmaceuticalsVaccines

AstraZeneca returns fostamatinib program rights to Rigel

04-06-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) and US partner Rigel Pharmaceuticals (Nasdaq: RIGL) today…

Anti-Arthritics/RheumaticsAstraZenecafostamatinibLicensingPharmaceuticalResearchRigel Pharmaceuticals

GlaxoSmithKline buys rights to MorphoSys RA drug candidate for up to $577 million

04-06-2013

German biotech firm MorphoSys (FSE: MOR) yesterday (June 3) saw its shares leap as much as 6%, as it…

Anti-Arthritics/RheumaticsFinancialLicensingPharmaceutical

AbbVie/Eisai's Humira has best clinical profile among psoriatic arthritis treatments

03-06-2013

Based on clinical data and the opinions of interviewed thought leaders interviewed by health care advisory…

AbbVieAnti-Arthritics/RheumaticsAstellas PharmaBiotechnologyCimziaEisaiEuropeHumiraMarkets & MarketingNorth AmericaPharmaceuticalUCB

Research briefs: Lilly's Forteo; Genmab/GSK's Arzerra; AstraZeneca's Symbicort

30-05-2013

US drug major Eli Lilly (NYSE: LLY) has reported new data demonstrating that Forteo (teriparatide) significantly…

Anti-Arthritics/RheumaticsArzerraAstraZenecaEli LillyForteoGenmabGlaxoSmithKlineOncologyPharmaceuticalResearchRespiratory and PulmonarySymbicort

Amgen and Astellas link up on drugs for unmet medical needs in Japan

29-05-2013

World leading independent biotech firm Amgen (Nasdaq: AMGN) has joined forces with Japanese drug major…

AmgenAnti-Arthritics/RheumaticsAsia-PacificAstellas PharmaBiotechnologyCardio-vascularOncologyPharmaceuticalResearch

Proposal to list Roche's Neulastim and Actemra in New Zealand

24-05-2013

New Zealand's Pharmaceutical Management Agency PHARMAC has announce the approval of a proposal to list…

ActemraAnti-Arthritics/RheumaticsAsia-PacificNeulastimOncologyPharmaceuticalPricingRegulationRoche

Benefits of Diane 35 and generics outweigh risks in specific patient group, says EMA unit; other actions

17-05-2013

The European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) has concluded that…

almitrineAnti-Arthritics/RheumaticsBayerDermatologicalsDiane-35EuropeOsseorPharmaceuticalProtelosRegulation

AbbVie to pay $50 million to expand GLPG0634 deal with Galapagos to Crohn's disease

17-05-2013

US drugmaker AbbVie (NYSE: ABBV) says it is extending its deal with Belgium-based Galapagos (Euronext:…

AbbVieAnti-Arthritics/RheumaticsGalapagosGLPG0634Inflammatory diseasesLicensingPharmaceuticalResearch

Neovacs moving forward in rheumatoid arthritis, say analysts

17-05-2013

French biotech firm Neovacs (Alternext Paris: ALNEV) intends to initiate a Phase IIb trial with its lead…

Anti-Arthritics/RheumaticsBiotechnologyFinancialLicensingNeovacsResearch

Bayer initiates Ph III Stivarga study in liver cancer; Sanofi enrolls sarilumab patients

15-05-2013

German drug major Bayer (BAYN: DE) says that patient enrollment is underway for RESORCE (Regorafenib…

Anti-Arthritics/RheumaticsBayerOncologyPharmaceuticalRegeneronResearchSanofisarilumabStivarga

Third milestone for Neovacs in the Tracker program for rheumatoid arthritis

13-05-2013

French biotech firm Neovacs (Alternext Paris: ALNEV), a leader in active immunotherapies for the treatment…

Anti-Arthritics/RheumaticsBiotechnologyFinancialNeovacsResearch

Novartis' Ilaris gets new indication of childhood arthritis from US FDA

10-05-2013

Swiss pharmaceutical major Novartis (NIVN: VX) said this morning (May 10) that the US Food and Drug Administration…

Anti-Arthritics/RheumaticsNorth AmericaPharmaceuticalRare diseasesRegulation

Concert Pharma in $300 million-plus deal with Celgene

07-05-2013

Privately-held biotech firm Concert Pharmaceuticals said yesterday (May 6) that it has entered into a…

Anti-Arthritics/RheumaticsapremilastBiotechnologyCelgeneConcert PharmaceuticalsInflammatory diseasesLicensingOncologyResearch

Merck & Co wins Fosamax federal bellwether trial over atypical femur fracture claims

30-04-2013

A US has jury found in favor of pharma giant Merck & Co (NYSE: MRK) in the Glynn versus Merck case in…

Anti-Arthritics/RheumaticsFosamaxLegalMerck & CoNorth AmericaPharmaceutical

82 to 106 of 297 results

Back to top